167 related articles for article (PubMed ID: 38519377)
21. High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis.
Singh JA; Ohe C; Smith SC
Pathol Int; 2018 May; 68(5):265-277. PubMed ID: 29665139
[TBL] [Abstract][Full Text] [Related]
22. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
[TBL] [Abstract][Full Text] [Related]
23. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges.
Mohanty SK; Lobo A; Cheng L
Hum Pathol; 2023 Jun; 136():123-143. PubMed ID: 36084769
[TBL] [Abstract][Full Text] [Related]
24. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
25. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
26. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
27. New and emerging renal entities: a perspective post-WHO 2016 classification.
Trpkov K; Hes O
Histopathology; 2019 Jan; 74(1):31-59. PubMed ID: 30565301
[TBL] [Abstract][Full Text] [Related]
28. "Collecting duct carcinoma of the kidney: diagnosis and implications for management".
Cabanillas G; Montoya-Cerrillo D; Kryvenko ON; Pal SK; Arias-Stella JA
Urol Oncol; 2022 Dec; 40(12):525-536. PubMed ID: 34116936
[TBL] [Abstract][Full Text] [Related]
29. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
30. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
31. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Surg Pathol Clin; 2022 Dec; 15(4):713-728. PubMed ID: 36344185
[TBL] [Abstract][Full Text] [Related]
32. [Characterization of different renal cell carcinoma entities].
Rupp NJ; Moch H
Urologe A; 2020 Feb; 59(2):135-141. PubMed ID: 31974661
[TBL] [Abstract][Full Text] [Related]
33. [2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].
Bellal S; Kammerer-Jacquet SF; Rioux-Leclercq N;
Ann Pathol; 2024 May; ():. PubMed ID: 38729793
[TBL] [Abstract][Full Text] [Related]
34. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
35. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Clin Lab Med; 2023 Jun; 43(2):275-298. PubMed ID: 37169446
[TBL] [Abstract][Full Text] [Related]
36. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
37. Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means.
Przybycin CG
Adv Anat Pathol; 2024 May; 31(3):147-156. PubMed ID: 38329413
[TBL] [Abstract][Full Text] [Related]
38. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
39. Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification.
Udager AM; Mehra R
Arch Pathol Lab Med; 2016 Oct; 140(10):1026-37. PubMed ID: 27684973
[TBL] [Abstract][Full Text] [Related]
40. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification.
Inamura K
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
